Transaction · 0001193125-26-384042

Barrow Robert

Barrow Robert, CEO, reported a transaction classified as grant at Definium Therapeutics, Inc. involving 40000.000000 shares for an estimated $0.00. Reported holdings after the transaction were 1513663.000000 shares. The stored filing text includes a detected 10b5-1 reference.

grantSEC transaction code ACEO
DFTXDefinium Therapeutics, Inc.
Trade date
Sep 02, 2026
Filing date
Sep 05, 2026
View on SEC Insider profile
Estimated value$0Shares × reported price
Shares traded40.0k$0.00 per share
Holdings after1.51MDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

DFTX price since this filing

Daily closing prices, with the filing date and available return windows
DFTX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -7.3%1w ago +0.0%1d ago +0.0%
Returns since7d -13.7%30d -17.0%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
grant
Code A
Identifier
0001193125-26-384042
Common Shares
Transaction date
Sep 02, 2026
Filed Sep 05, 2026, 01:30 AM · 3d delay
Shares
40,000 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
1,513,663 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership 10b5-1 Detected
Filing-only score

-26 points

Compact filing score computed from stored Form 4 facts. Version v1.

Low filing signal

This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • grant_or_award-22 points

    transaction_code = A

    Grant or award transactions are scheduled compensation, not discretionary.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Executive Officer

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The common shares represent the first tranche of performance share units granted effective February 3, 2026. Each performance share unit represented a contingent right to receive one common share bas…

  2. F2

    Amount includes 417 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026.

  3. F3

    Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested performance restricted stock units, pursuant to sell-to-cover elections u…

  4. F4

    The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 3, 2026 at prices ranging from $37.46 to $38.94. The Reporting Person undertakes to p…

Original filing · 0001193125-26-384042
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

DFTX